WO2001085710A1 - Composes anticancereux, procede de fabrication, et compositions pharmaceutiques renfermant ces composes - Google Patents
Composes anticancereux, procede de fabrication, et compositions pharmaceutiques renfermant ces composes Download PDFInfo
- Publication number
- WO2001085710A1 WO2001085710A1 PCT/IB2001/000748 IB0100748W WO0185710A1 WO 2001085710 A1 WO2001085710 A1 WO 2001085710A1 IB 0100748 W IB0100748 W IB 0100748W WO 0185710 A1 WO0185710 A1 WO 0185710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- andrographolide
- disorders
- diabetes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 211
- 238000000034 method Methods 0.000 title claims description 51
- 238000002360 preparation method Methods 0.000 title claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 230000008569 process Effects 0.000 title claims description 17
- 230000001093 anti-cancer Effects 0.000 title description 6
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical class C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims abstract description 58
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 239000012453 solvate Substances 0.000 claims abstract description 28
- 208000037803 restenosis Diseases 0.000 claims abstract description 21
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 20
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 20
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims description 150
- -1 alkenoyl Chemical group 0.000 claims description 124
- 229910052739 hydrogen Inorganic materials 0.000 claims description 69
- 239000001257 hydrogen Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- 208000035475 disorder Diseases 0.000 claims description 34
- 125000003435 aroyl group Chemical group 0.000 claims description 33
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 33
- 206010022489 Insulin Resistance Diseases 0.000 claims description 32
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 30
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 30
- 208000011580 syndromic disease Diseases 0.000 claims description 30
- 230000037396 body weight Effects 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- 208000008589 Obesity Diseases 0.000 claims description 19
- 125000001589 carboacyl group Chemical group 0.000 claims description 19
- 150000002431 hydrogen Chemical group 0.000 claims description 19
- 235000020824 obesity Nutrition 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 239000013585 weight reducing agent Substances 0.000 claims description 18
- 206010020772 Hypertension Diseases 0.000 claims description 17
- 102000016267 Leptin Human genes 0.000 claims description 17
- 108010092277 Leptin Proteins 0.000 claims description 17
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 17
- 229940039781 leptin Drugs 0.000 claims description 17
- BCMGADYLSRDSFW-WPWPTVPKSA-N (3e,4s)-3-[2-[(4ar,6as,7r,10as,10br)-3,3,6a,10b-tetramethyl-8-methylidene-1,4a,5,6,7,9,10,10a-octahydronaphtho[2,1-d][1,3]dioxin-7-yl]ethylidene]-4-hydroxyoxolan-2-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H]3[C@@]([C@H]2CCC1=C)(C)COC(O3)(C)C)\C=C1/[C@H](O)COC1=O BCMGADYLSRDSFW-WPWPTVPKSA-N 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 15
- 208000029078 coronary artery disease Diseases 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical group 0.000 claims description 15
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 15
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 15
- 238000007796 conventional method Methods 0.000 claims description 14
- 230000002519 immonomodulatory effect Effects 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 239000011737 fluorine Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
- BIBPDMPNXWHNPK-YRQIKJSESA-N 14-Acetylandrographolide Natural products O=C(O[C@H]1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@]23C)/C(=O)OC1)C BIBPDMPNXWHNPK-YRQIKJSESA-N 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000005647 linker group Chemical group 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- BIBPDMPNXWHNPK-QJAZYMEMSA-N [(3s,4e)-4-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]-5-oxooxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1COC(=O)\C1=C\C[C@H]1[C@]2(C)CC[C@@H](O)[C@@](C)(CO)[C@H]2CCC1=C BIBPDMPNXWHNPK-QJAZYMEMSA-N 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000005035 acylthio group Chemical group 0.000 claims description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims 16
- 201000004792 malaria Diseases 0.000 claims 16
- 208000036142 Viral infection Diseases 0.000 claims 8
- 230000009385 viral infection Effects 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000000078 anti-malarial effect Effects 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 239000003430 antimalarial agent Substances 0.000 abstract description 4
- 230000002443 hepatoprotective effect Effects 0.000 abstract description 4
- 239000002955 immunomodulating agent Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 168
- 238000006243 chemical reaction Methods 0.000 description 126
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 96
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 57
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 57
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000002904 solvent Substances 0.000 description 32
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 229960001866 silicon dioxide Drugs 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 28
- 239000003480 eluent Substances 0.000 description 25
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 229940086542 triethylamine Drugs 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 239000007832 Na2SO4 Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 244000118350 Andrographis paniculata Species 0.000 description 7
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 0 CCC(*[C@@](CC1)[C@@](C)(COC(CC)=O)C(CCC2=C)[C@@]1(C)*2=CC=C([C@@](CO1)OC(CNC(OC(C)(C)C)=O)=O)C1=O)=O Chemical compound CCC(*[C@@](CC1)[C@@](C)(COC(CC)=O)C(CCC2=C)[C@@]1(C)*2=CC=C([C@@](CO1)OC(CNC(OC(C)(C)C)=O)=O)C1=O)=O 0.000 description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical class CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229910006124 SOCl2 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical class CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- IMUSLIHRIYOHEV-ZETCQYMHSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C IMUSLIHRIYOHEV-ZETCQYMHSA-N 0.000 description 2
- BZPHCEZGTOFOPH-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione;hydrofluoride Chemical compound F.BrN1C(=O)CCC1=O BZPHCEZGTOFOPH-UHFFFAOYSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 2
- HJBWJAPEBGSQPR-GQCTYLIASA-N 3,4-dimethoxycinnamic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1OC HJBWJAPEBGSQPR-GQCTYLIASA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229910021583 Cobalt(III) fluoride Inorganic materials 0.000 description 2
- HJBWJAPEBGSQPR-UHFFFAOYSA-N DMCA Natural products COC1=CC=C(C=CC(O)=O)C=C1OC HJBWJAPEBGSQPR-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001175 calcium sulphate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- WZJQNLGQTOCWDS-UHFFFAOYSA-K cobalt(iii) fluoride Chemical compound F[Co](F)F WZJQNLGQTOCWDS-UHFFFAOYSA-K 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012351 deprotecting agent Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910003480 inorganic solid Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 238000010583 slow cooling Methods 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- FQFKTKUFHWNTBN-UHFFFAOYSA-N trifluoro-$l^{3}-bromane Chemical compound FBr(F)F FQFKTKUFHWNTBN-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YIIRVUDGRKEWBV-FZOOCBFYSA-N (3e)-3-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]furan-2-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/C=COC1=O YIIRVUDGRKEWBV-FZOOCBFYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WTGVJERCTXWBLZ-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-hydroxybenzoic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C1=CC=CC=C1O WTGVJERCTXWBLZ-BTJKTKAUSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- XMJAJFVLHDIEHF-UHFFFAOYSA-N 14-deoxy-11, 12-didehydroandrographolide Natural products OCC1(C)C(O)CCC2(C)C1CCC(=C)C2C=CC1=CCOC1=O XMJAJFVLHDIEHF-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- NIRCAUPPZAUKDX-UHFFFAOYSA-N 5-benzyl-2-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-6-methylpyridazin-3-one Chemical compound O=C1C=C(CC=2C=CC=CC=2)C(C)=NN1CN(CC1)CCN1C1=CC=CC(Cl)=C1 NIRCAUPPZAUKDX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- MCJDJBIZJISMOR-UAPXLDCWSA-N CC(C)([C@H](C/C=C(\[C@@H](CO1)OC(C)=O)/C1=O)[C@@](C)(CC1)C(C2)[C@](C)(COC(C)=O)[C@@H]1OC(C)=O)C2OC(C)=O Chemical compound CC(C)([C@H](C/C=C(\[C@@H](CO1)OC(C)=O)/C1=O)[C@@](C)(CC1)C(C2)[C@](C)(COC(C)=O)[C@@H]1OC(C)=O)C2OC(C)=O MCJDJBIZJISMOR-UAPXLDCWSA-N 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 235000021513 Cinchona Nutrition 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 229910018162 SeO2 Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- KJFJXGDQSMGFTO-GSGGYZLZSA-N [(1r,2r,4as,5r,8as)-2-acetyloxy-5-[(2e)-2-[(4s)-4-acetyloxy-2-oxooxolan-3-ylidene]ethyl]-1,4a-dimethyl-6-methylidene-3,4,5,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl acetate Chemical compound C([C@H]1[C@]2(C)CC[C@H]([C@@]([C@H]2CCC1=C)(C)COC(=O)C)OC(C)=O)\C=C1/[C@H](OC(C)=O)COC1=O KJFJXGDQSMGFTO-GSGGYZLZSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- XMJAJFVLHDIEHF-YSDSKTICSA-N dehydroandrographolide Natural products C([C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)=CC1=CCOC1=O XMJAJFVLHDIEHF-YSDSKTICSA-N 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- WNYIBZHOMJZDKN-UHFFFAOYSA-N n-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
Definitions
- the present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates.
- the present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates.
- the novel derivatives of andrographolide have the general formula (I),
- R 1 , R 2 and R 3 may be same or different and independently represent hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, alkenoyl, aroyl, heteroafoyl, aralkanoyl, aralkenoyl, heteroaralkanoyl, heteroaralkenoyl, sulfonyl group or a group -(CO)- -R 5 where W represents O, S or NR 6 , wherein R 6 represents hydrogen or (CrC 6 )alkyl group, R 5 represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl or aroyl or OR 2 and OR 3 together form a substituted or unsubstituted 6 or 7 membered cyclic structure containing carbon and oxygen atoms; R 4 represents hydrogen, halogen or XR 7 where X represents O,
- the andrographolide derivatives represented by general formula (I) defined above of the present invention are useful for treating cancer and other proliferative diseases including but not limited to herpes simplex virus types I and II (HSN I and HSN II) and human immunodeficiency (HIN).
- the compounds of the present invention axe also useful in the treatment of psoriasis, restenosis, atherosclerosis and other cardiovascular disorders.
- the compounds of the present invention are also useful as antiviral, antimalarial, antibacterial, hepatoprotective, immunomodulating agents and for the treatment of metabolic disorders.
- the anticancer activity exhibited may be through cytotoxic activity, antiproliferation, cell cycle kinase inhibition or may be through cell differentiation.
- novel compounds of formula (I) are also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia, body weight reduction, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease and other cardiovascular disorders.
- the present invention also relates to pharmaceutical compositions containing compounds of general formula (I) or mixtures thereof.
- the present invention also relates to a process for the preparation of the above- defined compounds of general formula (I), their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates.
- the plant andrographis paniculata is extensively used in medicine as a bitter tonic, febrifuge and in bowel complaints (Glossary of Indian Medicinal Plants., Ed. R. ⁇ . Chopra, S. L. ⁇ ayar, I.C. Chopra, pl8, 1996; The useful plants of India, Ed. By S. B. Ambasta, p39, 1992).
- the plant is useful in the treatment of bacterial infections (Int. J. Crude Drug Res. 1990, 28(4), p273-283; Drugs of the Future 1990, 15(8) p809-816). It is reported to possess antimalarial (Int. J. Pharmacognosy,f l992, 30(4), p263-274; J.
- Cell cycle kiriases are naturally occurring enzy nes involved in regulation of the cell cycle (Progress in Cell Cycle Research, 1995, 1, p351-363).
- Typical enzymes include the cyclin-depehdent kinases (cdk) cdkl, cdk2, cdk4, cdk5, cdk6 and Wee-1 kinase.
- cdk cyclin-depehdent kinases
- cdk cyclin-depehdent kinases
- Japanese patent application JP 63-88124 discloses a mixture of at least two compounds of formula Via, VIb,
- R 1 , R 2 , R 3 , R 4 and R 5 represent hydrogen or lower alkanoyl group and their activity as antitumorogenic agents.
- DASM dehydroandrographolide succinic acid monoester prepared from andrographolide of the formula II is found to be inhibiting HIV virus and nontoxic to the H9 cell at the concentrations of 50-200 ⁇ g/ml and was inhibitory to HIV-l(IIIB) at the minimal concentration of 1.6-3.1 ⁇ g/ml (Proc. Soc. Exp. Biol. Med., 1991, 197, p59-66).
- the plant Andrographis paniculata is also reported to inhibit proprotein convertases-1, -7 and furin possibly by suppressing the proteolytic cleavage of envelops glycoprotein gp 160 of HIV, which is known to be PC-mediated, particularly by furin and PC (Biochem. J., 1999, 338, 107-113)
- compositions containing one or more ingredients obtained from the plants Valeariana officinalis and / or A. paniculata were disclosed to have antiviral, antineoplastic, antibacterial and immunomodulatory activity.
- novel andrographolide derivatives have been prepared, screened and reported in the above said prior-art literature for their anticancer activity, they are not showing interesting activity.
- novel andrographolide derivatives useful for treating cancer, HSN, HIV, psoriasis, restenosis, atherosclerosis, cardiovascular disorders also useful ds antiviral, antimalarial, antibacterial, hepatoprotective, immunornodulating agents arid for treatment of metabolic disorders, which are potent at lower doses arid havirig better efficacy with lower toxicity ⁇ we focussed our research efforts in preparing the novel andrographolide derivatives of the formula (I) as defined above.
- the main objective of the present invention is, therefore, to provide novel andrographolide derivatives of the formula (I) as defined above, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions co ⁇ taihirig them or their mixtures.
- Another objective of the present invention is to provide pharmaceutical compositions containing compounds of formula (I), their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates containing them or their mixtures in combination with suitable carriers, solvents, diluents and other media normally erhployed in preparing such compositions.
- Still another objective of the present invention is to provide pharmaceutical compositions containing compounds of formula (I), their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, containing them or their mixtures in combination with one or more pharmaceutically acceptable active compounds with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.
- Still another objective of the present invention is to provide a process for the preparation of novel Andrographolide derivatives of the formula (I) as defined above, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having enhanced activity with little or no toxic effect or reduced toxic effect.
- R 1 , R 2 and R 3 may be same or different and independently represent hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, aralkenoyl, heteroaralkanoyl, heteroaralkenoyl, sulfonyl group or a group -(CO)-W-R 5 where W represents O, S or NR 6 , wherein R 6 represents hydrogen or (d-C 6 )alkyl group, R 5 represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl or aroyl or OR 2 and OR 3 together form a substituted or unsubstituted 6 or 7 membered cyclic structure containing carbon and oxygen atoms; R 4 represents hydrogen, halogen or XR 7 where X represents O, S,
- Suitable groups represented by R 1 , R 2 and R 3 include hydrogen, substituted or unsubstituted, linear or branched (C Cs) alkyl group such as methyl, ethyl, n-propyl, iso-propyl and the like; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; heteroaryl group such as pyridyl, furyl, thiophenyl and the like, the heteroaryl group may be substituted; aralkyl such as benzyl, phenethyl and the like, the aralkyl group may be substituted; heteroaralkyl group such as pyridylmethyl, pyridylethyl, furanmethyl, furanethyl and the like, the heteroaralkyl group may be substituted; (C 2 -C 8 ) alkanoyl group such as ethanoyl, propanpyl, butano
- the substituerits oh R 9 and R 10 include hydroxy, halogen such as fluorine, chlorine, bromine and the like; nitro, cyano or amino, (Ci-C 6 )alkyl, (Q-C ⁇ alkoxy, aryl or aroyl groups.
- Suitable groups represented by R 4 include hydrogen, halogen such as fluorine, chlorine, bromine arid the like; or XR 7 where R 7 represents hydrogen or linear or branched (Q-Cs) alkyl group such as methyl, ethyl, n-propyl, iso-propyl and the like, the alkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group rnay be substituted; aralkyl such as benzyl, pheriethyl and the like, the aralkyl group r ⁇ ay be substituted; (C 3 -C 8 ) alkenoyl group such as propenoyl, butenoyl, pentenoyl and the like, the alkenoyl group may be substituted; (C 2 -C 8 ) alkanoyl group such as ethanoyl, pr ⁇ pahoyl, butanoyl
- Suitable groups represented by R 5 include ( -C ⁇ alkyl such as methyl, ethyl, n- propyl and the like, the (CrC 6 )alkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aralkyl such as benzyl, phenethyl and the like, the aralkyl group may be substituted; aroyl group such as benzoyl and the like, the aroyl group may be substituted.
- the substituents on the alkyl group, aromatic moiety of the aryl group, aralkyl group or aroyl group include halogen atom such as fluorine, chlorine and bromine; amino group, cyano, hydroxy, nitro, trifluoroethyl, (CrC 6 ) alkyl, (C ⁇ -C 6 ) alkoxy.
- Suitable groups represented by R 6 include hydrogen, substituted or unsubstituted
- ( -C ⁇ ) alkyl such as methyl, ethyl, n-propyl and the like.
- the substituents on the alkyl group include halogen atom such as fluorine, chlorine and bromine; amino group, cyano, hydroxy, nitro, trifluoroethyl, ( -C ⁇ ) alkyl, (CrC 6 ) alkoxy.
- R 1 , R 2 , R 3 , R 7 and R 8 may be selected from cyano, hydroxy, nitro, thio, halogen atom such as fluorine, chlorine, bromine and the like; substituted or unsubstituted groups selected from linear or branched (CpCg) alkyl group such as methyl, ethyl, n-propyl, iso-propyl and the like; amino, mono or disubstituted amino group; alkanoyl group such as ethanoyl, propanoyl, butanoyl and the like; thio(C 1 -C 8 )alkyl such as thiomethyl, thioethyl, thiopropyl and the like; (C 1 -C 6 )alkoxy group such as methoxy, ethoxy, propyloxy, butyloxy and the like; aroyl group such as benzoyl and the like; acyloxy group
- (C C 8 )alkylthio group such as methylthio, ethylthio, propylthio and the like; heteroarylthio group such as pyridylthio, furylthio, thiophenylthio, benzothiazolethio, purinethio, benzimidazolethio, pyrimidinethio and the like; acylthio group such as acetylthio, propanoylthio, butanoylthio and the like; aralkylthio group such as benzylthio, phenylethylthio, phenylpropylthio and the like; arylthio group such as phenylthio, napthylthio and the like; ( -C ⁇ alkylseleno such as methylseleno, ethylseleno, propylselen
- R 1 , R 2 , R 3 , R 5 , R 7 and R 8 represent disubstituted aryl
- the two substituents on the adjacent carbon atoms form a linking group such as -X-CH 2 -Y-, -X- CH 2 -CH 2 -Y-, where X and Y may be same or different and independently represent O, NH, S or CH 2 .
- salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; salts of organic bases such as N,N'-diacetylethylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethariol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'- diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline,
- Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoate's, methanesulphonates, benzdates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
- acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoate's, methanesulphonates, benzdates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
- solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
- Particularly useful compounds according to present invention include:
- the present invention also provides a process for the preparation of novel andrographolide of the general formula (I), where R 1 , R 2 and R 3 may be same or different and independently represent hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, aralkenoyl, heteroaralkanoyl, heteroalkenoyl, s ⁇ lf riyl group or a group -(CO)-W-R 5 where W represents O, S or NR 6 , wherein R 6 represents hydrogen or (d-C 6 )alkyl group, R 5 represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl or aroyl or OR 2 arid OR 3 together for n a substituted or unsubstituted 6 or 7 membe e
- R 1 , R 2 arid R 3 are as defined above and L represents hydroxy or a leaving group such as halogen atorri like fluorine, chlorine, bromine or iodine; p-tolueriesulforiate, methanesulfonate, trifluorornethanesulfonate and the like; or an alkanoate such as acetate, propanoate, butanoate arid the like, to produce a compound of formula (I), where all symbols are as defined earlier and R 4 represents hydrogen.
- reaction of a compound of formula (VII) with R'-L and R 2 -L and R 3 -L, to produce a compound of formula (I) may be carried out in the presence of dicyclohexylcarbodiirriide (DCC), diethyl azadicarboxylate (DEAD), diisopropyl azadicarboxylate (DIAD) and the like.
- the reaction may be carried out in the absence or presence of a base selected frofn triethylamine, pyridine, dimethyl aminopyridine and the like.
- the reaction rnay be carried out in the presence of solvents such as dichlofomethane, chloroform, C 6 H 6 , dimethyl sulfoxide, r ⁇ ethanol, ethanol and the like or fnixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 200 °C, preferably at a temperature in the range of 20 °C to 160 °C and the reaction tin ⁇ e may range from 2 to 12 h, preferably from 2 to 10 h.
- the compounds of formula (I) may also be prepared by a process, which comprises:
- R 4 represents hydrogen
- P 1 and P 2 may be same or different and represent hydrogen, trityl, t-butyl dimethyl silyl, pivaloyl arid the like or esters such as acetate, propionate, benzoate and the like or together may form methylene dioxy, isopropylidene, benzylidene, 1 -phenyl ethylidene, carbonate and the like,
- R -L (IX) where R 1 and L have the meanings given above to produce a compound of formula (X), where R 1 , R 4 , P 1 and P 2 are as defined above,
- R 1 and R 4 have the meanirigs given above,
- the protection of a compound of formula (VII) may be carried out using trityl chloride, t-butyldimethylsilyl chloride, pivaloyl chloride, dimethylsulfoxide, acetone, 2,2-dimethoxy propane, trimethyl ortho acetate, benzaldehyde, p-methoxy benzaldehyde and the like.
- the reaction may be carried out in the presence of a suitable catalyst such as SOCl 2 , H 2 SO , HClO 4 , pyridinium p-toluene sulphonate, pyridine, p-toluene sulfonic acid, dimethyl aminopyridine, and the like.
- the reaction may be carried out in the absence or presence of suitable solvent such as benzene, DMF, DMSO, acetonitrile, DCM, and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 60 °C, preferably at a temperature in the range of 20 °C to 40 °C.
- the reaction time may range from 2 to 6 h, preferably from 2 to 4 h.
- the reaction of a compound of formula (VIII) with a compound of formula (IX) to produce a compound of formula (X) may be carried out in the presence of dicyclohexylcarbodiimide (DCC), diethyl azadicarboxylate (DEAD), diisopropyl azadicarboxylate (DIAD) and the like.
- the reaction may be carried out in the absence or presence of a base selected from triethylamine, pyridine, dimethyl aminopyridine and the like.
- the reaction may be carried out in the presence of solvents such as dichloromethane, chloroform, C 6 H 6 , dimethyl sulfoxide, methanol, ethanol and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 200 °C, preferably at a temperature in the range of 20 °C to 160 °C and the reaction time may range from 2 to 12 h, preferably from 2 to 10 h.
- the deprotection of a compound of formula (X) to produce a compound of formula (XI) r ⁇ ay be carried out using deprotecting agent such as acetic acid, hydrochloric acid, formic acid, trifluoroacetic acid and the like.
- the reaction may be carried in the presence of suitable solvent such as water, THF, dioxane, DCM, CHC1 3 , methanol and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 60 °C, preferably at a temperature in the range of 20 °C to 40 °C.
- the reaction time may range from 2 to 6 h, preferably from 2 to 4 h.
- reaction of compound of formula (XI) with R 2 -L and R 3 -L, to produce a compound of formula (I) may be carried out in the presence of dicyclohexylcarbodiimide (DCC), diethyl azadicarboxylate (DEAD), diisopropyl azadicarboxylate (DIAD) and the like.
- the reaction may be carried out in the absence or preserice of a base selected from triethylamine, pyridine, dimethyl aminopyridine and the like.
- the reaction may be carried out in the presence of solvents such as dichloromethane, chloroform, C 6 H 6 , dimethyl sulfoxide, methanol, ethanol and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 200 °C, preferably at a temperature in the range of 20 °C to 160 °C and the reaction time may range from 2 to 12 h, preferably from 2 to 10 h.
- the compound of formula (XII) represents a compound of formula (I) when X represents O.
- Convertion the compound of formula (I) to produce a compound of formula (XII) may be carried out in the presence of reagents such as SeO , t-Bu0 2 H, H 2 O 2 and the like.
- reagents such as SeO , t-Bu0 2 H, H 2 O 2 and the like.
- the reaction may be carried out in the presence of solvents such as DCM, CHC1 3 , benzene, THF, dioxane, DMF, methanol, ethanol and the like or mixtures thereof.
- the temperature and duration of the reaction may be maintained in the range of 0 to 30°C and 3 to 48 h respectively.
- the reaction of compound of formula (XII) with R 7 -L to produce a compound of formula (I) may be carried out in the presence of dicyclohexylcarbodiimide (DCC), diethyl azadicarboxylate (DEAD), diisopropyl azadicarboxylate (DIAD) and the like.
- the reaction may be carried out in the absence or presence of a base selected from triethylamine, pyridine, dimethyl aminopyridine and the like.
- the reaction may be carried out in the presence of solvents such as dichloromethane, chloroform, C 6 H 6 , dimethyl sulfoxide, methanol, ethanol and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 200 °C, preferably at a temperature in the range of 20°C to 160°C and the reaction time may range from 2 to 12 h, preferably from 2 to 10 h.
- the compound of formula (XII) represents a compound of formula (I) when X represents O.
- (XII) may be carried out in the presence of reagents such as SeO 2 , t-Bu0 2 H, H 2 O 2 and the like.
- the reaction may be carried out in the presence of solvents such as DCM, CHC1 3 , benzene, THF, dioxane, DMF, methanol, ethanol and the like or mixtures thereof.
- solvents such as DCM, CHC1 3 , benzene, THF, dioxane, DMF, methanol, ethanol and the like or mixtures thereof.
- the temperature and duration of the reaction may be maintained in the range of 0 to 30°C and 3 to 48 h respectively.
- the conversion of coriipound of formula (XII) to compound of formula (I) may be carried out using halogenating agents such as thionyl chloride, thionyl bromide, phosphonyl chloride, PC1 5 , PBr 3) bromine trifluoride, N-bromosuccinimide-hydrogen fluoride(NBS-HF), cobalt(III)fluoride, lithium fluoride, potassium fluoride, sodium fluoride, ceasium fluoride, potassium iodide, sodium iodide, iodine, iodine cerium(IV)ammonium nitrate or R 7 -L where R 7 and L are as defined above.
- halogenating agents such as thionyl chloride, thionyl bromide, phosphonyl chloride, PC1 5 , PBr 3) bromine trifluoride, N-bromosuccinimide-hydrogen fluoride(NBS-HF), cobalt(
- the reaction may be carried out in the presence of solvents such as ether, dichloromethane, chloroform, DMF, DMSO and the like;
- the reaction may be carried out in the range of- 40°C to 160°C.
- the duration of the reaction may range from 1 to 6 h.
- a process for the preparation of the compound of formula (I) where R 4 represents halogen and other symbols are as defined earlier, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates which comprises: reacting the compound of formula (I) where R 4 represents hydrogen and all other symbols are as defined earlier with suitable halogenating agent to produce a compound of formula (I), where R 4 represents halogen atom such as fluorine, chlorine, bromine or iodine
- the reaction of compound of formula (I) where R 4 represents hydrogen with halogenating agents, to produce a compound of formula (I) where R 4 represents halogen may be carried out in the presence of reagents such as N-bromosucinimide(NBS), N- chlorosucinimide(NCS), N-iodosucinimide(NIS), bromine, chlorine, POCl 3 , PC1 3 , PBr 3 , SOCl , bromine trifluor
- the reaction may be carried out in the presence of solvents such as DCM, CHC1 3 , benzene, THF, dioxane, DMF, methanol, ethanol and the like or mixtures thereof.
- solvents such as DCM, CHC1 3 , benzene, THF, dioxane, DMF, methanol, ethanol and the like or mixtures thereof.
- the temperature and duration of the reaction may be maintained in the range of -80 to 32°C and 3 to 48 h respectively.
- R 1 represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, alkenoyl, aroyl, aralkanoyl, aralkenoyl, heteroaroyl,, heteroaralkanoyl, heteroaralkenoyl, sulfonyl groups or a group -(CO)-W-R 5 where W represents O, S or NR , wherein R represents hydrogen or (C ⁇ -C 6 )alkyl group, R 5 represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl or •aroyl; R 4 represents hydrogen; P 1 and P 2 may be same or different and independently represent trityl, t-butyldimethylsilyl, pivaloyl and the like or esters such as acetate, propionate, benzoate and the like or P 1 and P 2 together may
- the present invention also provides a process for the preparation of the compound of formula (X), their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates, which comprises: (i) protecting the hydroxy groups present on carbons 3 or 19 or 3 and 19 together in the compound of formula (Nil) with suitable protecting groups using conventional methods to produce a compound of formula (NIII), where R 4 represents hydrogen; P 1 and P 2 may be same or different and represent hydrogen, trityl, t-butyl dimethyl silyl, pivaloyl and the like or esters such as acetate, propionate, benzoate and the like or together may form methylene dioxy, isopropylidene, benzylidene, 1 -phenyl ethylidene, carbonate and the like,
- R 1 , R 4 , P 1 and P 2 are as defined earlier.
- the protection of a compound of formula (VII) may be carried out using trityl chloride, t-butyldimethylsilyl chloride, pivaloyl chloride, dimethylsulfoxide, acetone, 2,2-dimethoxy propane, trimethyl ortho acetate, benzaldehyde, p-methoxy benzaldehyde and the like.
- the reaction may be carried out in the presence of a suitable catalyst such as SOCl 2 , H 2 SO , HClO , pyridinium p-toluene sulphonate, pyridine, p-toluene sulfonic acid, dimethyl aminopyridine, and the like.
- the reaction may be carried out in the absence or presence of suitable solvent such as benzene, DMF, DMSO, acetonitrile, DCM, and the like or mixtures thereof.
- the reactiori may be carried out ' at a temperature in the range of 0 °C to 60 °C, preferably at a temperature in the range of 20 °C to 40 °C.
- the reaction tirr ⁇ e may range fr ⁇ rri 2 to 6 h, preferably frorn 2 to 4 h.
- the reaction of a compound of formula (VIII) with a compound of formula (IX) to produce a cor ⁇ pound of forrnula (X) may be carried out in the presence of dicyclohexylcarbodiimide (DCC), diethyl azadicarboxylate (DEAD), diisopropyl azadicarboxylate (DIAD) and the like.
- the reaction may be carried out in the absence or presence of a base selected from triethylamine, ' pyridine, dimethyl arniriopyridine and the like.
- the reaction rfiay be carried out iri the presence of solvents such as dichloromethane, chloroform, C 6 H 6 , dirriethyl sulfoxide, methanol, ethariol and the like or ftiixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 200 °C, preferably at a temperature in the range of 20 °C to 160 °C arid the reaction time may range from 2 to 12 h, preferably from 2 to 10 h.
- R 1 represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, alkenoyl, aroyl, aralkanoyl, aralkenoyl, heteroaroyl,, heteroa alkarioyl, heteroaralkenoyl, sulfonyl groups or a group -(CO)-W- R 5 where W represents O, S or NR 6 , wherein R 6 represents hydrogen or (C ⁇ -C 6 )alkyl group, R 5 represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl or aroyl and R 4 represents hydrogen.
- the present invention also provides a process for the preparation of the compound of formula (XI), their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates, which comprises: (i) protecting the hydroxy groups present on carbons 3 or 19 or 3 and 19 together in the compound of formula (VII) with suitable protecting groups using conventional methods to produce a compound of formula (VIII),
- R 4 represents hydrogen
- P 1 and P 2 may be same or different and represent hydrogen, trityl, t-butyl dimethyl silyl, pivaloyl and the like or esters such as ace ate, propionate, benzoate and the like or together may form methylene dioxy, isopropylidene, benzylidene, 1 -phenyl ethylidene, carbonate and the like,
- R 1 and R 4 have the meanings given above.
- the protection of a compound of formula (VII) may be carried out using trityl chloride, t-butyldimethylsilyl chloride, pivaloyl chloride, dimethylsulfoxide, acetone, 2,2-dimethoxy propane, trimethyl ortho acetate, benzaldehyde, p-methoxy benzaldehyde and the like.
- the reaction may be carried out in the preserice of a suitable catalyst such as SOCl 2 , H 2 SO , HClO 4 , pyridi ⁇ ium p-toluene sulphonate, pyridine, p-toluene sulfonic acid, dimethyl aminopyridine, and the like.
- a suitable catalyst such as SOCl 2 , H 2 SO , HClO 4 , pyridi ⁇ ium p-toluene sulphonate, pyridine, p-toluene sulfonic acid, dimethyl aminopyridine, and the like.
- the reaction may be carried out in the absence or presence of suitable solvent such as benzene, DMF, DMSO, acetonitrile, DCM, and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 60 °C, preferably at a temperature in the range of 20 °C to 40 °
- the reaction time may range from 2 to 6 h, preferably from 2 to 4 h.
- the reaction of a compound of formula (VIII) with a compound of formula (IX) to produce a compound of formula (X) may be carried out in the presence of dicyclohexylcarbodiimide (DCC), diethyl azadicarboxylate (DEAD), diisopropyl azadicarboxylate (DIAD) and the like.
- the reaction may be carried out in the absence or presence of a base selected from triethylamine, pyridine, dimethyl aminopyridine and the like.
- the reaction may be carried out in the presence of solvents such as dichloromethane, chloroform, C 6 H 6 , dimethyl sulfoxide, methanol, ethanol and the like or mixtures thereof.
- solvents such as dichloromethane, chloroform, C 6 H 6 , dimethyl sulfoxide, methanol, ethanol and the like or mixtures thereof.
- the reaction may be carried out at a temperature in the range of 0 °C to 200 °C, preferably at a temperature in the range of 20 °C to 160 °C and the reaction time may range from 2 to 12 h, preferably from 2 to 10 h.
- the deprotection of a compound of formula (X) to produce a compound of formula (XI) may be carried out using deprotecting agent such as acetic acid, hydrochloric acid, formic acid, trifluoroacetic acid and the like.
- deprotecting agent such as acetic acid, hydrochloric acid, formic acid, trifluoroacetic acid and the like.
- the reaction may be carried in the presence of suitable solvent such as water, THF, dioxane, DCM, CHC1 3 , methanol and the like or mixtures thereof.
- the reaction may be carried out at a
- the reaction time may range from 2 to 6 h* preferably from 2 to 4 h.
- Suitable protecting groups in any of the above-mentioned reactions are those used conventionally in the art.
- the methods of formation and removal of such protecting groups are those conventional methods appropriate to the fnolecule being protected.
- the compound of formula (I) when produced through an intermediate compound, conventional functional group transformations such as hydrolysis, reduction or oxidation may be carried out.
- the compound of formula (I) where R 1 , R 2 or R 3 are multi substituted and the two substituents may form a linking group -X-(CR ⁇ R 12 ) n -Y-, which may be converted to a compound of formula (I), where R 1 , R 2 or R 3 are multisubstituted and the substituents are independent.
- the pharmaceutically acceptable salts are prepared by reacting the compounds of formula (I) wherever applicable with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesiui ⁇ hydroxide and the like, in solvents like ether, THF, methanol, t- butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, tromethamine, guanidine and their derivatives etc. may also be used.
- acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
- acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic
- stereoisomers of the compounds of formula (I) forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods.
- Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid and the like or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al. in "Enantiomers, Recemates and Resolution” (Wiley Interscience, 1981).
- polymorphs of cor ⁇ pound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperature ' s; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polyrhorphs may also be obtained by heating or melting the compound followed by gradual or slow cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray data or such other techniques.
- Pharmaceutically acceptable solvates of compound of formula (I) forming part of this invention may be prepared by conventional methods such as dissolving the compounds of formula (I) in solvents such as water, methanol, ethanol etc., preferably water and recrystallizing by using different crystallization techniques.
- the present invention also envisages pharmaceutical compositions containing compounds of the formula (I) defined earlier, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates or their mixtures in combination with the usual pharmaceutically employed carriers, solvents, diluents and other media normally employed in preparing such compositions.
- the pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc.
- compositions typically contain from 1 to 25 %, preferably 1 to 15 % by weight of active compound, the remainder of the composition may be pharmaceutically acceptable carriers, diluents or solvents and also contain other active ingredients.
- the compounds of the formula (I) as defined above are clinically administered to mammals, including man, via either oral or parenteral routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally.
- the dosage is in the range of about 0.01 to about 100 mg / kg body weight of the subject per day or preferably about 0.01 to about 30 mg / kg body weight p ' er day administered singly or as a divided dose.
- Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions.
- the active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above.
- the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
- the pharmaceutical coriipositions may, if desired, contain additional components such as', fiavourarits, sweeteners, excipients arid the like.
- the compounds cari be corribined with sterile aqueous or organic media to form injectable solutions or suspensions.
- injectable solutions or suspensions for example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds, the injectable soluti ns prepared in this r ⁇ anner can then be administered intravenously, LTDraperit ⁇ neally, subcutaneously, i . or intrarriuscularly, with intrariiuscular administration being preferred in humans.
- the invention is explained in detail in the examples given below which are provided by way of illustration only arid therefore should not be construed to limit the scope of the invention.
- N-Isopropyl isocyanate was prepared by adding a solution of isopropyl amine(1.2 ml) and triethyl amine (1.87 ml) in toluene (10 ml) to a stirred solution of tri- phosgene (1.25 g) in 30 ml toluene and heated at 100°C for 1 h. The reaction mixture was cooled, to this a solution of 3,19-isopropylidene andrographolide (700 mg)(obtained in example 1) and triethyl amine (1.87 ml) in toluene (25 ml) was added. The contents were stirred for 48 h at room temperature. The reaction was monitored by TLC.
- Step 2 To a solution of 14-[4'S,5'R-(N-t-butoxycarbonyl)-2',2'-dimethyl-4'-phenyl-5'- oxazolidine]carbonyl-3,l 9-isopropylidene andrographolide obtained in step 1, in acetic anhydride (50 ml) at 80°C, zinc chloride (500 mg) was added in 100 mg portions over a period of 30 min. Stirring continued for another 30 min. The reaction was monitored by TLC. After confirming the completion of the reaction, the reaction mixture was poured into water, extracted with dichloromethane, dried over Na 2 SO 4 and concentrated.
- Example 17 3,19-Diacetyl-14-[4'S,5'R-(N-t-b ⁇ toxycarbonyl)-2',2'-dimethyl-4'- phenyl-5'-oxazolidine]carbonyl andrographolide
- Step 2 14-[4'S,5'R-(N-t-butoxycarbony l)-2 ' ,2 ' -dimethyl-4 ' -phenyl-5 ' -oxazolidine] carbonyl andrographolide (1.65 g), which was used further without purification.
- Step 2 14-[4'S,5'R-(N-t-butoxycarbonyl)-2',2'-dimethyl-4'-phenyl-5'-oxazolidine] carbonyl andrographolide (1.15 g) obtained above was refluxed in acetic andhydride (40 ml) for about 15 min. The reaction was monitored by TLC.
- Step 3 14-(N-Boc-glycinyl)andrographolide (200 mg) (obtained in step 2) was refluxed in propionic anhydride (20 ml) for about 10 min. The reaction was monitored by TLC. After confirming the completion of the reaction, the reaction mixture was cooled, poured into water, extracted with dichloromethane. The organic layer was separated, dried over Na 2 SO 4 and concentrated.
- 14-(N-Boc-glycinyl)andrographolide (300 mg) (obtained in example 20, step 2) was refluxed in acetic anhydride (15 ml) for about 15 min. The reaction was monitored by TLC. After confirming the completion of the reaction, the reaction mixture was cooled, poured into water, extracted with dichloromethane. The organic layer was separated, dried over Na 2 SO 4 and concentrated.
- Step 1 A mixture of 3,19-isopropylidene andrographolide (500 mg), obtained in example 1, calcium sulphate (555 mg), silver oxide (500 mg) and ethyl iodide (5 ml) were stirred at room temperature for 18 h. The reaction was monitored by TLC. After confirming the completion of the reaction, the inorganic solids were filtered, washed with dichloromethane.
- Step 1 A mixture of 3,19-isopropylidene andrographolide (500 mg) (obtained in example 1), calcium sulphate (500 mg), silver oxide (480 mg) and methyl iodide (1.5ml) were stirred at room temperature for 18h. The reaction was monitored by TLC. After confirming the completion of the reaction, the reaction mixture was diluted with dichloromethane, inorganic solids were filtered, washed with dichloromethane.
- Step 2 14-O-methy 1-3,19-isopropylidene andrographolide (550 mg) obtained in step 1, was treated with 25 ml of methanolic HCl (25 ml methanol : 200 ⁇ l HCl) at room temperature for about 2-5 min. The reaction was monitored by TLC.
- reaction mixture was diluted with dichloromethane, washed with saturated aq. NaHCO 3) followed by water and dried over Na 2 SO 4 .
- Step 3 A mixture of 14-(3,4-dimethoxy)cinnamoyl andrographolide (650 mg) and acetic anhydride (10 ml) was refluxed for about 15 min. The reaction was monitored by TLC.
- 3,14-Diacetyl-19-trityl andrographolide (800 mg) obtained in step 1 was treated with a mixture of formic acid and dichloromethane (1:1) 20 ml for 10 min at room temperature. The reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with aq. NaHC0 3 followed by water and dried over Na 2 SO 4 . The residue obtained after " removal of solvent was chromatographed over a column of silica gel (230-400 riiesh; using chlorform : acetone
- Anti-cancer activity The compounds prepared in the present invention exhibited good in vitro anti- cancer activity towards various human tumor cell lines.
- test compound was screened against a battery of cell lines representing eight different types of cancers.
- 1X10 4 cells were seeded into each well of 96 well plate in lOO ⁇ L volume of RPMI 1640 medium containing antibiotics and 10% FCS.
- test compounds were evaluated at five 10 fold dilutions ranging from 100 to 0.01 ⁇ M.
- medium with vehicle was added to control wells and the plates were further incubated. After 48 h of incubation, plates were terminated by Sulforhodamine B method.
- the optical density which is proportional to protein mass, is then read by automated spectrophotometric plate reader at a wavelength of 515 nm. Readings were transferred to a microcomputer and mean 50 % Growth Inhibition (GI50).
- the compounds of the present invention showed anticaricer activity, which can be seen from the data given below:
- mice Male C57BL/KsJ-db/db mice of 8 to 14 weeks age, having body weight range of 35 to 60 grams, bred at Dr. Reddy's Research Foundation (DRF) animal house, were used in the experiment. The mice were provided with standard feed (National Institute of Nutrition (NIN), India) and acidified water, ad libitum. The animals having more than 350 mg / dl blood sugar were used for testing. The number of animals in each group was 4.
- Test compounds were suspended in chemophore/DMSO/H 2 O and administered to test group at a dose of 1 mg to 500 mg / kg through oral gavage daily for 6 days.
- the control group received vehicle (dose 10 ml / kg).
- the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.
- the random blood sugar and triglyceride levels were measured by collecting blood (100 ⁇ l) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma.
- the plasma glucose and triglyceride levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO 4 oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, India) methods respectively.
- Body weight of the animals were measured at the beginning and at the end of the study period.
- mice Male Swiss albino mice (SAM) were obtained from NIN and housed in DRF animal house. All these animals were maintained under 12 hour light and dark cycle at 25 + 1 °C. Animals were given standard laboratory chow (NIN,
- test compounds were administered orally to Swiss albino mice at 30 to 500 mg/kg/day dose for 6 days. Control mice were treated with vehicle
- the blood samples were collected in fed state 1 hour after drag administration on 0 and 6 day of treatment.
- the blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for triglyceride (Wieland, O. Methods of Enzymatic analysis. Bergermeyer, H. O., Ed., 1963. 211 - 214; Trinder, P. Ann. Clin. Biochem. 1969. 6 : 24 - 27).
- Measurement of plasma triglyceride was done using commercial kits (Dr. Reddy's Diagnostic Division, India).
- Human CD4+ T cell line PM-1 used in the assay was cultured in RPMI-1640 medium containing 10% Fetal bovine serum, 2g/L sodium bicarbonate, 100,000 units/L Pencillin-G arid 100 mg/L streptomycin. Healthy PM-1 cells were plated on the first day in a 96 well plate at 2* 10 6 cells per well. After 24 h HIV-l/MN was added to the culture and incubated for 2 h for infection. Cells were washed twice with PBS to remove the virus in the culture. Different concentrations of DRF compounds ranging from 10 "4 to 10 "8 M were added to the culture and incubated for 96 h.
- the viability of cells was then assessed by standard MTT assay and the viral antigen P24 levels were estirriated by ELISA method. Based on the MTT assay values the P 24 antigen values were corrected. All the samples were tested in triplicates and the average was used for calculations. AZT was used as standard compound for comparision.
- Human lymphocytes were isolated from whole blood by using Ficoll Hypaque Plus (Amersham). On day one, 1 million lymphocytes were seeded into each well of 96 well plate in 100 ⁇ L volume of RPMI 1640 medium ' containing 10%FCS and Phytohemagglutitin A at 1 ⁇ g/well concentration. Plates were incubated at 37°C in CO 2 incubator for 24 h. Test compounds at various concentrations were added to test wells and only medium with vehicle was added to control wells. After 48 h of incubation 0.5 mCi of tritiated thymidine was added to each well. After 24 h of thymidine addition the cells were harvested and the incorporated radioactivity was determined. Stimulation Index (SI) was calculated using the formula,
- a ⁇ Average CPM of treated wells
- a c Average CPM of control wells.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des dérivés d'andrographolide, leurs stéréoisomères, leurs polymorphes, leurs sels pharmaceutiquement acceptables et leurs solvates pharmaceutiquement acceptables. Ces dérivés, représentés par la formule générale (I), sont utiles pour le traitement des maladies suivantes: cancer, HSV, VIH, psoriasis, resténose, athérosclerose et autres affections cardiovasculaires. Ils sont également utiles comme agents antiviraux, antipaludiques, antibactériens, hépatoprotecteurs, immunomodulateurs, et aussi pour le traitement des troubles du métabolisme.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001256570A AU2001256570A1 (en) | 2000-05-05 | 2001-05-03 | Novel anticancer compounds: process for their preparation and pharmaceutical compositions containing them |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN354/MAS/2000 | 2000-05-05 | ||
IN354MA2000 | 2000-05-05 | ||
IN434MA2000 | 2000-06-08 | ||
IN434/MAS/2000 | 2000-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001085710A1 true WO2001085710A1 (fr) | 2001-11-15 |
Family
ID=26324892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2001/000748 WO2001085710A1 (fr) | 2000-05-05 | 2001-05-03 | Composes anticancereux, procede de fabrication, et compositions pharmaceutiques renfermant ces composes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001256570A1 (fr) |
WO (1) | WO2001085710A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087127A1 (fr) * | 2003-03-31 | 2004-10-14 | Council Of Scientific And Industrial Research | Composition hepatoprotectrice synergique et methode correspondante |
JP2008519066A (ja) * | 2004-11-08 | 2008-06-05 | コーネル リサーチ ファンデーション インコーポレーティッド | ウイルス感染症を処置するためのアンドログラフォライド(andrographolide)誘導体 |
US7794753B2 (en) | 2003-03-31 | 2010-09-14 | Council Of Scientific And Industrial Research | Synergistic hepatoprotective composition and a method thereof |
CN102716122A (zh) * | 2012-07-03 | 2012-10-10 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备治疗糖尿病药物中的应用 |
CN103145665A (zh) * | 2012-04-12 | 2013-06-12 | 江西青峰药业有限公司 | 17-氢-9-去氢-14,17-环-穿心莲内酯-19-硫酸酯化物、制备方法及其制备药物用途 |
CN103224492A (zh) * | 2013-04-15 | 2013-07-31 | 南京工业大学 | 14-芳基醚穿心莲內酯衍生物及其制备方法和应用 |
CN104119253A (zh) * | 2013-04-24 | 2014-10-29 | 江西青峰药业有限公司 | 一种穿心莲内酯衍生物的药物组合物及其制备方法与用途 |
CN104119251A (zh) * | 2013-04-24 | 2014-10-29 | 江西青峰药业有限公司 | 9-去氢-穿心莲内酯-17-磺酸-16-羧酸或其盐、制备方法及其制备药物用途 |
WO2016065264A1 (fr) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Dérivés de diterpénoïdes et leurs procédés d'utilisation |
CN106432153A (zh) * | 2016-10-13 | 2017-02-22 | 四川理工学院 | 一类含硫穿心莲内酯衍生物、其药物组合物、合成方法、在制备治疗前列腺癌药物中的应用 |
CN108084122A (zh) * | 2018-01-30 | 2018-05-29 | 北海开元生物科技有限公司 | 一种高纯度穿心莲内酯的提取方法 |
CN108129468A (zh) * | 2018-01-29 | 2018-06-08 | 四川理工学院 | 一类阿司匹林衍生物及其制法和应用 |
CN108904446A (zh) * | 2018-06-11 | 2018-11-30 | 中山大学 | 一种动脉斑块微环境响应的载药纳米胶束的制备方法及应用 |
CN109568265A (zh) * | 2017-09-28 | 2019-04-05 | 神威药业集团有限公司 | 一种穿心莲内酯纳米混悬剂 |
CN113173896A (zh) * | 2021-04-14 | 2021-07-27 | 张洪胜 | 一种抗氧化活性的阿魏酸衍生物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001742A1 (fr) * | 1989-07-28 | 1991-02-21 | Ruffles, Graham, Keith | Compositions biologiquement actives |
WO1996017605A1 (fr) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Utilisation de composes andrographolide dans le traitement ou l a prevention de la pathogenicite de certaines maladies |
US5833994A (en) * | 1997-01-08 | 1998-11-10 | Paracelsian, Inc. | Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection |
WO2001043704A1 (fr) * | 1999-12-14 | 2001-06-21 | Avon Products, Inc. | Compositions de traitement de la peau mediant les communications de cellule a cellule |
-
2001
- 2001-05-03 WO PCT/IB2001/000748 patent/WO2001085710A1/fr active Application Filing
- 2001-05-03 AU AU2001256570A patent/AU2001256570A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001742A1 (fr) * | 1989-07-28 | 1991-02-21 | Ruffles, Graham, Keith | Compositions biologiquement actives |
WO1996017605A1 (fr) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Utilisation de composes andrographolide dans le traitement ou l a prevention de la pathogenicite de certaines maladies |
US5833994A (en) * | 1997-01-08 | 1998-11-10 | Paracelsian, Inc. | Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection |
WO2001043704A1 (fr) * | 1999-12-14 | 2001-06-21 | Avon Products, Inc. | Compositions de traitement de la peau mediant les communications de cellule a cellule |
Non-Patent Citations (3)
Title |
---|
I.B. KOUL ET. AL.: "Effect of Diterpenes from Andrographis Paniculata on Antioxidant Defense System and Lipid Peroxidation", INDIAN JOURNAL OF PHARMACOLOGY, vol. 26, no. 4, December 1994 (1994-12-01), pages 296 - 300, XP001008618 * |
S. SAXENA ET. AL.: "High-Performance Thin Layer Chromatographic Analysis of Hepatoprotective Diterpenoids from Andrographis Paniculata.", PHYTOCHEMICAL ANALYSIS, vol. 11, no. 1, 2000, pages 34 - 6, XP001008189 * |
T. MATSUDA ET. AL.: "Cell Differentiation Inducing Diterpenes form Andrographis Paniculata", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 42, no. 6, 1994, pages 1216 - 25, XP000567717 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7794753B2 (en) | 2003-03-31 | 2010-09-14 | Council Of Scientific And Industrial Research | Synergistic hepatoprotective composition and a method thereof |
WO2004087127A1 (fr) * | 2003-03-31 | 2004-10-14 | Council Of Scientific And Industrial Research | Composition hepatoprotectrice synergique et methode correspondante |
JP2008519066A (ja) * | 2004-11-08 | 2008-06-05 | コーネル リサーチ ファンデーション インコーポレーティッド | ウイルス感染症を処置するためのアンドログラフォライド(andrographolide)誘導体 |
US8445533B2 (en) | 2004-11-08 | 2013-05-21 | Cornell Research Foundation, Inc. | Andrographolide derivatives to treat viral infections |
CN103145665B (zh) * | 2012-04-12 | 2014-12-31 | 江西青峰药业有限公司 | 17-氢-9-去氢-14,17-环-穿心莲内酯-19-硫酸酯化物、制备方法及其制备药物用途 |
CN103145665A (zh) * | 2012-04-12 | 2013-06-12 | 江西青峰药业有限公司 | 17-氢-9-去氢-14,17-环-穿心莲内酯-19-硫酸酯化物、制备方法及其制备药物用途 |
CN102716122A (zh) * | 2012-07-03 | 2012-10-10 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备治疗糖尿病药物中的应用 |
CN102716122B (zh) * | 2012-07-03 | 2014-06-25 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备治疗糖尿病药物中的应用 |
CN103224492A (zh) * | 2013-04-15 | 2013-07-31 | 南京工业大学 | 14-芳基醚穿心莲內酯衍生物及其制备方法和应用 |
CN103224492B (zh) * | 2013-04-15 | 2016-01-13 | 南京工业大学 | 14-芳基醚穿心莲內酯衍生物及其制备方法和应用 |
CN104119253B (zh) * | 2013-04-24 | 2015-12-09 | 江西青峰药业有限公司 | 一种穿心莲内酯衍生物的药物组合物及其制备方法与用途 |
CN104119251A (zh) * | 2013-04-24 | 2014-10-29 | 江西青峰药业有限公司 | 9-去氢-穿心莲内酯-17-磺酸-16-羧酸或其盐、制备方法及其制备药物用途 |
CN104119253A (zh) * | 2013-04-24 | 2014-10-29 | 江西青峰药业有限公司 | 一种穿心莲内酯衍生物的药物组合物及其制备方法与用途 |
CN104119251B (zh) * | 2013-04-24 | 2015-12-09 | 江西青峰药业有限公司 | 9-去氢-穿心莲内酯-17-磺酸-16-羧酸或其盐、制备方法及其制备药物用途 |
WO2016065264A1 (fr) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Dérivés de diterpénoïdes et leurs procédés d'utilisation |
CN106432153A (zh) * | 2016-10-13 | 2017-02-22 | 四川理工学院 | 一类含硫穿心莲内酯衍生物、其药物组合物、合成方法、在制备治疗前列腺癌药物中的应用 |
CN109568265A (zh) * | 2017-09-28 | 2019-04-05 | 神威药业集团有限公司 | 一种穿心莲内酯纳米混悬剂 |
CN109568265B (zh) * | 2017-09-28 | 2021-09-28 | 神威药业集团有限公司 | 一种穿心莲内酯纳米混悬剂 |
CN108129468A (zh) * | 2018-01-29 | 2018-06-08 | 四川理工学院 | 一类阿司匹林衍生物及其制法和应用 |
CN108129468B (zh) * | 2018-01-29 | 2020-09-29 | 四川理工学院 | 一类阿司匹林衍生物及其制法和应用 |
CN108084122B (zh) * | 2018-01-30 | 2021-05-07 | 北海开元生物科技有限公司 | 一种高纯度穿心莲内酯的提取方法 |
CN108084122A (zh) * | 2018-01-30 | 2018-05-29 | 北海开元生物科技有限公司 | 一种高纯度穿心莲内酯的提取方法 |
CN108904446A (zh) * | 2018-06-11 | 2018-11-30 | 中山大学 | 一种动脉斑块微环境响应的载药纳米胶束的制备方法及应用 |
CN108904446B (zh) * | 2018-06-11 | 2021-05-11 | 中山大学 | 一种动脉斑块微环境响应的载药纳米胶束的制备方法及应用 |
CN113173896A (zh) * | 2021-04-14 | 2021-07-27 | 张洪胜 | 一种抗氧化活性的阿魏酸衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2001256570A1 (en) | 2001-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410590B1 (en) | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them | |
WO2001085710A1 (fr) | Composes anticancereux, procede de fabrication, et compositions pharmaceutiques renfermant ces composes | |
US6486196B2 (en) | Anticancer compounds: process for their preparation and pharmaceutical compositions containing them | |
KR0172590B1 (ko) | 2-히드록시메틸-5-(5-플루오로시토신-1-일)-1,3-옥사티올란의 항비루스 활성 및 그것의 분해방법 | |
KR0128661B1 (ko) | 시클로부탄 유도체 및 그 제조 방법 | |
RU2126405C1 (ru) | (-)-4-амино-5-фтор-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1h)-пиримидин- 2-он, смесь его энантиомеров, способы их получения, способ лечения | |
KR100357541B1 (ko) | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 | |
CA2093020A1 (fr) | Derives de nucleoside | |
WO1994004154A9 (fr) | NUCLEOSIDES ENANTIOMERIQUEMENT PURS DE β-D-DIOXOLANE | |
US6576662B2 (en) | Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them | |
PT895981E (pt) | Compostos de terfenilo e medicamentos contendo os mesmos | |
WO2001085709A2 (fr) | Nouveaux composes presentant une activite anticancereuse et compositions pharmaceutiques les contenant | |
EP0743308A2 (fr) | Composé quinazoléine et composition contre les tumeurs le contenant comme composé actif | |
EP0788495A2 (fr) | Nucleosides l-erythrosyle | |
AP675A (en) | Isolation of natirally occuring isoflavanone and some clinical uses thereof. | |
KR20000006339A (ko) | 아라비노실아데닌유도체 | |
FR2621918A1 (fr) | 2',3'-didesoxy-4-thio-uridines, procede de preparation de ces substances et medicaments qui en contiennent | |
KR19990064240A (ko) | 새로운 면역억제제 및 항바이러스 약제로서의 리피드알코올 | |
CA2429539A1 (fr) | Derives de piperazine dibenzosuberanyle et agents surmontant la resistance aux medicaments contenant ces derives | |
US20050043396A1 (en) | 5-Benzoylamino-1,3-dioxacyclanes, the method for preparing the same and their use as PKC inhibitor | |
CN109912584B (zh) | 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用 | |
CN101230015A (zh) | 含酰胺取代基的取代桂皮酸衍生物及其肿瘤细胞毒性 | |
KR920006903B1 (ko) | 디메틸-4,4'-디메톡시-5,6,5',6,6'-디메틸렌-디옥시비페닐-2,2'-디카르복실레이트를 유효성분으로 하는 인체 및 표유동물의 종양형성 억제제 및 종양형성 억제용 약학적 조성물 | |
CN117343072A (zh) | 一种1-取代肉桂酰基-2-氧代石蒜碱类化合物及其制备方法和应用 | |
US5155111A (en) | DDB as an agent against BEL-7402 human hepatocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |